Ainos, Inc. (AIMD) Q1 2025 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2025. Ainos, Inc. is an AI-driven healthcare and technology company focused on scent digitization (AI Nose), AI-powered diagnostics, and novel therapeutics (VELDONA). The company operates as a single segment and is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $106,207 | $20,729 |
| Gross Profit | $87,974 | ($6,025) |
| Operating Loss | ($3,162,871) | ($3,120,091) |
| Net Loss | ($3,286,022) | ($3,314,810) |
| Diluted EPS | ($0.21) | ($0.57) |
| Cash and Equivalents (End of Period) | $2,628,286 | $1,030,899 |
| Total Debt (Convertible Notes) | $12,000,000 | $12,000,000 |
| Accumulated Deficit | ($56,035,338) | ($41,200,965) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 412% to $106,207, driven primarily by $105,942 in recognized revenue from VOC sensing products related to a co-development agreement with NISD.
- Expense Trends: Research and Development (R&D) expenses decreased 17% to $1.72 million due to lower clinical trial fees and staffing costs. Conversely, Selling, General, and Administrative (SG&A) expenses increased 48% to $1.53 million, largely due to a significant rise in share-based compensation.
- Interest Expense: Interest expense surged 271% to $180,445, attributed to accrued interest on convertible notes issued in May 2024 with higher principal amounts.
- Cash Flow: Net cash used in operating activities improved to $1.22 million (from $1.49 million in Q1 2024). Financing activities provided only $14,605 in net proceeds from an "At The Market" (ATM) offering, a sharp decline from $777,500 in the prior year.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern for at least one year. The company has an accumulated deficit of over $56 million and expects to incur additional losses.
- Liquidity Strategy: Management plans to fund operations through existing cash ($2.6 million), potential debt financing, and equity offerings via the ATM facility. There is no assurance that additional financing will be available on acceptable terms.
- Strategic Developments: In March 2025, Ainos formed a strategic partnership with ugo, Inc., a Japanese robot developer, to integrate AI Nose technology into autonomous robots. The company continues to advance clinical studies for VELDONA (oral warts in HIV patients, Sjögren's syndrome) and AI Nose-based POCT devices (Ainos Flora, Ainos Pen).
- Risks: Key risks include the inability to secure future funding, foreign currency fluctuations (operations in Taiwan), and potential trade policy changes affecting international commerce.
- Subsequent Event: On April 30, 2025, the company repaid a $1.0 million convertible note to Li-Kuo Lee plus accrued interest of $132,650.
Investor Verification Checklist
- Cash Runway: Verify if the current cash balance of $2.6 million is sufficient to cover the projected burn rate given the $3.3 million quarterly net loss.
- Debt Maturity: Review the terms of the $12 million in convertible notes, specifically the maturity dates (May 2025 for the Lee Note, March 2027 for the ASE Note) and conversion prices.
- Revenue Sustainability: Assess the recurring nature of the $105k revenue from the NISD co-development and the status of the ceased COVID-19 test kit sales.
- Related Party Transactions: Scrutinize the $2 million convertible note from ASE Test, Inc. (a related party) and the terms of the recent amendment extending its maturity.
- Share Dilution: Monitor the impact of the 1.78 million shares issued in Q1 2025 (RSUs, special awards, ATM) on future earnings per share.